Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All montelukast studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMontelukastMontelukast (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Characteristics and outcomes of adult patients with asthma presenting with COVID-19: A comparative cohort study

Alhmoud et al., Qatar Medical Journal, doi:10.5339/qmj.2023.15
Sep 2023  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Hospitalization 13% Improvement Relative Risk Montelukast for COVID-19  Alhmoud et al.  Prophylaxis Is prophylaxis with montelukast beneficial for COVID-19? Retrospective 616 patients in Qatar (March - August 2020) No significant difference in hospitalization c19early.org Alhmoud et al., Qatar Medical J., September 2023 Favorsmontelukast Favorscontrol 0 0.5 1 1.5 2+
28th treatment shown to reduce risk in November 2021
 
*, now with p = 0.0045 from 8 studies.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 81 treatments. c19early.org
Retrospective 616 COVID-19 patients with asthma in Qatar showing no significant difference in hospitalization risk with montelukast use.
Although the 13% lower hospitalization is not statistically significant, it is consistent with the significant 17% lower hospitalization [8‑25%] from meta analysis of the 6 hospitalization results to date.
risk of hospitalization, 13.0% lower, OR 0.87, p = 0.61, treatment 111, control 505, adjusted per study, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alhmoud et al., 23 Sep 2023, retrospective, Qatar, peer-reviewed, median age 44.0, 10 authors, study period 10 March, 2020 - 10 August, 2020. Contact: ealhamoud@hamad.qa.
This PaperMontelukastAll
Characteristics and outcomes of adult patients with asthma presenting with COVID-19: A comparative cohort study
Eman Alhmoud, Raja Barazi, Mohammed Saad, Dania Al Khiyami, Reem El Ajez, Dana Bakdach, Ali Omrani, Wanis Ibrahim, Rasha El Anany, Moza Al-Hail
Qatar Medical Journal, doi:10.5339/qmj.2023.15
Background: Bronchial asthma affects about 20% of Qatar's population. The impact of asthma on COVID-19 outcomes is controversial. The aim of this study was to explore the impact of asthma on COVID-19 outcomes and the predictors of COVID-19related morbidity and mortality in a cohort of asthma patients infected by COVID-19. Methods: This is a retrospective cohort study of adult patients with asthma infected with COVID-19, who were recruited from Hamad Medical Corporation (HMC), the main healthcare system in Qatar. Patients were matched to a control group of non-asthmatic COVID-19 patients (1:2) based on sex, age, and other comorbidities. Results: Between March and August 2020, 616 patients with asthma met the inclusion criteria. The need for hospitalization among patients with asthma was independently associated with older age (adjusted odds ratio [aOR] for 10 years, 1.32; 95% confidence interval [CI], 1.13-1.54; p = 0.001) and hypertension (aOR, 2.4; 95% CI, 1.43-3.93; p = 0.001) but not with the use of inhaled corticosteroids (ICS), long-acting beta2 agonists, montelukast, or tiotropium. Patients with asthma required less hospitalization for COVID-19 than non-asthmatic patients (28.2% vs. 37.3%, respectively; aOR, 0.59; 95% CI, 0.77-0.90; p < 0.001). However, admission to the intensive care unit (ICU) was comparable between both groups (3.3% vs. 2.2%; aOR, 1.64; 95% CI, 0.78-3.43; p = 0.193). No difference in mortality rate was observed between the two groups. 1
CONCLUSION Based on the results of the current study, older age and history of hypertension appear to be independently associated with COVID-19 hospitalization among patients with asthma. Patients with asthma had a lower risk of hospitalization, but not ICU admission, compared to non-asthmatic patients. Further research is warranted to explore the effects of different asthma phenotypes, ethnic backgrounds, and vaccination status on the outcomes of COVID-19 infections among this patient group. CONFLICT OF INTEREST The authors declare that there is no conflict of interest or financial disclosures to be disclosed. limitation of the study approval duration coupled with the available registry for matching. Extending the study period might have identified more patients with asthma and thus have resulted in a larger studied population. However, the advantage of such a cohort still exists in the fact that all included patients were still not vaccinated and thus helped in reducing the confounding effects of the vaccines on different COVID-19 outcomes. Second, given the retrospective nature of the study, along with the use of electronic health records to obtain the studied sample, misclassification and incomplete documentation issues are unavoidable and could have some impact on the internal validity of the study. Moreover, different studies have recently coupled the phenotype of asthma to COVID-19 severity. However, in our study, we have not recorded the different phenotypes of..
References
Alexander, Tajanlangit, Heyward, Mansour, Qato et al., Use and content of primary care office-based vs telemedicine care visits during the COVID-19 pandemic in the US, JAMA Netw Open, doi:10.1001/jamanetworkopen.2020.21476
Almazeedi, Al-Youha, Jamal, Al-Haddad, Al-Muhaini et al., Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait, EClinicalMedicine
Bergman, Ballin, Nordström, Nordström, Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: A nationwide study, Eur J Epidemiol
Bloom, Drake, Docherty, Lipworth, Johnston et al., Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: A national, multicentre prospective cohort study using the ISARIC WHO clinical characterisation protocol UK, Lancet Respir Med
Branco, Sato, Alberca, The possible dual role of the ACE2 receptor in Asthma and Coronavirus (SARS-CoV2) infection, Front Cell Infect Microbiol
Burjaq, Omar, Hammoudeh, Janahi, Asthma Management in Qatar: Environmental Challenges and Recommendations, J Environ Sci Public Health
Carli, Cecchi, Stebbing, Parronchi, Farsi, Asthma phenotypes, comorbidities, and disease activity in COVID-19: The need of risk stratification, Allergy
Chhiba, Patel, Vu, Chen, Guo et al., Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19, J Allergy Clin Immunol, doi:10.1016/j.jaci.2020.06.010
Choi, Park, Lee, Suh, Song et al., Effect of asthma and asthma medication on the prognosis of patients with COVID-19, Eur Respir J, doi:10.1183/13993003.02226-2020
Dessie, Zewotir, Mortality-related risk factors of COVID-19: A systematic review and metaanalysis of 42 studies and 423,117 patients, BMC Infect Dis
Dolby, Nafilyan, Morgan, Relationship between asthma and severe COVID-19: A national cohort study, Thorax, doi:10.1136/thoraxjnl-2021-218629
Griesel, Wagner, Mikolajewska, Stegemann, Fichtner et al., Inhaled corticosteroids for the treatment of COVID-19, Cochrane Database Syst Rev
Gude-Sampedro, Fernández-Merino, Ferreiro, Lado-Baleato, Espasandín-Domínguez et al., Development and validation of a prognostic model based on comorbidities to predict COVID-19 severity: A population-based study, Int J Epidemiol
Halpin, Faner, Sibila, Badia, Agisti, Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?, Lancet Respir Med
Hartnett, Kite-Powell, Devies, Coletta, Boehmer et al., Impact of the COVID-19 pandemic on emergency department visits -United States, MMWR Morb Mortal Wkly Rep
Hernandez-Galdamez, Block, Romo-Dueñas, Lima-Morales, Hernández-Vicente et al., Increased risk of hospitalization and death in patients with COVID-19 and pre-existing noncommunicable diseases and modifiable risk factors in Mexico, Arch Med Res
Izquierdo, Almonacid, González, Rio-Bermudez, Ancochea et al., The impact of COVID-19 on patients with asthma, Eur Respir J
Kaye, Theye, Smeenk, Gondalia, Barrett et al., Changes in medication adherence among patients with asthma and COPD during the COVID-19 pandemic, J Allergy Clin Immunol Pract
Lee, Son, Han, Jung, Park, Impact of comorbid asthma on severity of coronavirus disease (COVID-19), Sci Rep
Mahdavinia, Foster, Jauregui, Moore, Ab, Asthma prolongs intubation in COVID-19, J Allergy Clin Immunol Pract
Matsumoto, Saito, Does asthma affect morbidity or severity of COVID-19?, J Allergy Clin Immunol
Nystad, Hjellvik, Larsen, Ariansen, Helland et al., Underlying conditions in adults with COVID-19. Underliggende tilstander hos voksne med covid-19, Tidsskr Nor Laegeforen, doi:10.4045/tidsskr.20.0512
O'beirne, Salit, Kaner, Crystal, Strulovici-Barel, Up-regulation of ACE2, the SARS-CoV-2 receptor, in asthmatics on maintenance inhaled corticosteroids, Respir Res
Omrani, Almaslamani, Daghfal, Alattar, Elgara et al., The first consecutive 5000 patients with Coronavirus Disease 2019 from Qatar; a nation-wide cohort study, BMC Infect Dis
Peters, Sajuthi, Deford, Christenson, Rios et al., COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids, Am J Respir Crit Care Med, doi:10.1164/rccm.202003-0821
Ramakrishnan, Nicolau, Jr, Langford, Mahdi et al., Inhaled budesonide in the treatment of early COVID-19 (STOIC): A phase 2, open-label, randomised controlled trial, Lancet Respir Med
Rogliani, Lauro, Daniele, Chetta, Calzetta, Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: A benefit of inhaled corticosteroids?, Expert Rev Respir Med, doi:10.1080/17476348.2021.1850275
Santos, Lucena, Lima, Brito, Bay et al., Survival and predictors of deaths of patients hospitalised due to COVID-19 from a retrospective and multicentre cohort study in Brazil, Epidemiol Infect
Schultze, Walker, Mackenna, Morton, Bhaskaran et al., Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: An observational cohort study using the OpenSAFELY platform, Lancet Respir Med
Shi, Pan, Vasileiou, Robertson, Sheikh, Public Health Scotland and the EAVE II Collaborators. Risk of serious COVID-19 outcomes among adults with asthma in Scotland: A national incident cohort study, Lancet Respir Med
Sisó-Almirall, Kostov, Mas-Heredia, Vilanova-Rotllan, Sequeira-Aymar et al., Prognostic factors in Spanish COVID-19 patients: A case series from Barcelona, PLoS One
Sunjaya, Allida, Tanna, Jenkins, Asthma and COVID-19 risk: A systematic review and meta-analysis, Eur Respir J
Sunjaya, Allida, Tanna, Jenkins, Asthma and risk of infection, hospitalization, ICU admission and mortality from COVID-19: Systematic review and meta-analysis, J Asthma
Wang, Foer, Bates, Boyce, Zhou, Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19, J Allergy Clin Immunol
Yehia, Winegar, Fogel, Fakih, Ottenbacher et al., Association of race with mortality among patients hospitalized with coronavirus disease 2019 (COVID-19) at 92 US hospitals, JAMA Netw Open
Zhu, Hasegawa, Ma, Fujiogi, Jr et al., Association of asthma and its genetic predisposition with the risk of severe COVID-19, J Allergy Clin Immunol
{ 'indexed': { 'date-parts': [[2023, 10, 10]], 'date-time': '2023-10-10T12:42:29Z', 'timestamp': 1696941749294}, 'reference-count': 0, 'publisher': 'Hamad bin Khalifa University Press (HBKU Press)', 'issue': '3', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2023, 9, 23]]}, 'DOI': '10.5339/qmj.2023.15', 'type': 'journal-article', 'created': {'date-parts': [[2023, 7, 24]], 'date-time': '2023-07-24T21:30:31Z', 'timestamp': 1690234231000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Characteristics and outcomes of adult patients with asthma presenting with COVID-19: A ' 'comparative cohort study', 'prefix': '10.5339', 'volume': '2023', 'author': [ { 'given': 'Eman', 'family': 'Alhmoud', 'sequence': 'first', 'affiliation': [ { 'name': 'Pharmacy Department, Hamad Medical Corporation, Doha, Qatar. ' 'E-mail: ealhamoud@hamad.qa ORCID: 0000-0002-3871-7088'}]}, { 'given': 'Raja', 'family': 'Barazi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Pharmacy Department, Hamad Medical Corporation, Doha, Qatar. ' 'E-mail: ealhamoud@hamad.qa ORCID: 0000-0002-3871-7088'}]}, { 'given': 'Mohammed', 'family': 'Saad', 'sequence': 'additional', 'affiliation': [ { 'name': 'Pharmacy Department, Hamad Medical Corporation, Doha, Qatar. ' 'E-mail: ealhamoud@hamad.qa ORCID: 0000-0002-3871-7088'}]}, { 'given': 'Dania', 'family': 'Al Khiyami', 'sequence': 'additional', 'affiliation': [ { 'name': 'Pharmacy Department, Hamad Medical Corporation, Doha, Qatar. ' 'E-mail: ealhamoud@hamad.qa ORCID: 0000-0002-3871-7088'}]}, { 'given': 'Reem', 'family': 'El Ajez', 'sequence': 'additional', 'affiliation': [ { 'name': 'Pharmacy Department, Hamad Medical Corporation, Doha, Qatar. ' 'E-mail: ealhamoud@hamad.qa ORCID: 0000-0002-3871-7088'}]}, { 'given': 'Dana', 'family': 'Bakdach', 'sequence': 'additional', 'affiliation': [ { 'name': 'Pharmacy Department, Hamad Medical Corporation, Doha, Qatar. ' 'E-mail: ealhamoud@hamad.qa ORCID: 0000-0002-3871-7088'}]}, { 'given': 'Ali', 'family': 'Omrani', 'sequence': 'additional', 'affiliation': [ {'name': 'College of Medicine, Qatar University, Doha, Qatar'}, {'name': 'Department of Medicine, Hamad Medical Corporation, Doha, Qatar'}]}, { 'given': 'Wanis', 'family': 'Ibrahim', 'sequence': 'additional', 'affiliation': [ {'name': 'Weill Cornell Medicine - Qatar (WCM-Q), Qatar'}, {'name': 'College of Medicine, Qatar University, Doha, Qatar'}, {'name': 'Department of Medicine, Hamad Medical Corporation, Doha, Qatar'}]}, { 'given': 'Rasha', 'family': 'El Anany', 'sequence': 'additional', 'affiliation': [ { 'name': 'Pharmacy Department, Hamad Medical Corporation, Doha, Qatar. ' 'E-mail: ealhamoud@hamad.qa ORCID: 0000-0002-3871-7088'}]}, { 'given': 'Moza', 'family': 'Al-Hail', 'sequence': 'additional', 'affiliation': [ { 'name': 'Pharmacy Department, Hamad Medical Corporation, Doha, Qatar. ' 'E-mail: ealhamoud@hamad.qa ORCID: 0000-0002-3871-7088'}]}], 'member': '3277', 'container-title': 'Qatar Medical Journal', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.qscience.com/content/journals/10.5339/qmj.2023.15?crawler=true&mimetype=application/pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2023, 10, 9]], 'date-time': '2023-10-09T08:23:54Z', 'timestamp': 1696839834000}, 'score': 1, 'resource': {'primary': {'URL': 'https://www.qscience.com/content/journals/10.5339/qmj.2023.15'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 9, 23]]}, 'references-count': 0, 'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2023, 9, 23]]}}, 'URL': 'http://dx.doi.org/10.5339/qmj.2023.15', 'relation': {}, 'ISSN': ['0253-8253', '2227-0426'], 'subject': [], 'published': {'date-parts': [[2023, 9, 23]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit